| Literature DB >> 30386320 |
Masahiro Abe1,2,3, Yuki Kinjo1,4,5, Keigo Ueno1, Shogo Takatsuka1, Shigeki Nakamura1, Sho Ogura3, Muneyoshi Kimura3, Hideki Araoka3,6, Sota Sadamoto7, Minoru Shinozaki7, Kazutoshi Shibuya7, Akiko Yoneyama3,6, Mitsuo Kaku2, Yoshitsugu Miyazaki1.
Abstract
Objectives: Candida species are a major cause of hospital infections, including ocular candidiasis, but few studies have examined the propensities of specific species to invade the eye or the unique immunological responses induced. This study examined the frequency and characteristics of species-specific Candida eye infections by epidemiology and experiments using a mouse ocular candidiasis model.Entities:
Keywords: Candida albicans; candidemia; chemokines; cytokines; monocytes; neutrophils; ocular candidiasis
Year: 2018 PMID: 30386320 PMCID: PMC6199462 DOI: 10.3389/fmicb.2018.02477
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Epidemiological and medical characteristics of the patients in ocular candidiasis and non-ocular candidiasis groups.
| Demographic or clinical characteristics | Ocular candidiasis ( | Non-ocular candidiasis ( | Univariate analysis | Multivariate analysis |
|---|---|---|---|---|
| Age, median years (range) | 74 (41–89) | 66.5 (20–93) | 0.04 | 0.57 |
| Male/Female | 14 / 6 | 62 / 18 | 0.56 | - |
| Fever, median °C (range)∗1 | 39.2 (36.0–40.1) | 38.4 (35.5–40.7) | 0.06 | 0.27 |
| Septic shock | 2 (10%) | 12 (15%) | 0.73 | - |
| Hematological malignancies∗2 | 2 (10%) | 31 (39%) | 0.02 | 0.31 |
| Solid organ malignancies | 10 (50%) | 28 (35%) | 0.30 | - |
| Diabetes mellitus | 6 (30%) | 15 (19%) | 0.36 | - |
| Liver cirrhosis | 1 (5%) | 1 (1%) | 0.36 | - |
| Chronic kidney diseases | 4 (20%) | 17 (22%) | >0.99 | - |
| Abdominal surgery | 2 (10%) | 8 (10%) | >0.99 | - |
| Central venous catheter insertion∗3 | 18 (90%) | 69 (87%) | >0.99 | - |
| Neutropenia (<500/ μL) | 0 (0%) | 15 (19%) | 0.04 | >0.99 |
| Corticosteroid usage | 11 (55%) | 41 (52%) | 0.81 | - |
| Other immunosuppressive agents | 1 (5%) | 18 (23%) | 0.11 | 0.27 |
| 16 (80%) | 10 (13%) | <0.01 | <0.01 | |
| Non-albicans | 5 (25%) | 69 (87%) | ||
| Breakthrough candidemia | 0 (0%) | 27 (34%) | <0.01 | 0.99 |
| Micafungin | - | 25 (93%) | ||
| Liposomal amphotericin B | - | 2 (7%) | ||
| - | ||||
| BDG value (median, pg/mL) | 49.3 | 20.5 | 0.14 | - |
| Positive rate of serum BDG | 15 (75%) | 45 (58%) | 0.20 | 0.16 |
| The overall 30-day mortality rate | 2 (10%) | 18 (23%) | 0.35 | - |
Candida species distribution in ocular candidiasis and non-ocular candidiasis groups.
| Ocular candidiasis ( | Non-ocular candidiasis ( | |
|---|---|---|
| 16 | 10 | |
| Non-albicans | 5 | 69 |
| 2 | 39 | |
| 2 | 17 | |
| 1 | 5 | |
| 3 | ||
| 2 | ||
| 1 | ||
| 1 | ||
| 1 |